"There is no such situation in any country in the world": the country's chief diabetologist - about the Russian drug for obesity President of the Russian Diabetes Association, corresponding member of the Russian Academy of Sciences Gagik Galstyan in the round table of RBC highly appreciated the Russian drug Tirliday. This is the local tyrzepatide - a new generation of drugs for the treatment of obesity and type 2 diabetes. According to the doctor, the situation is unique: a high-quality drug, which in composition repeats the American original, costs many times less. "There is no such situation in any country in the world. My respect to the colleagues who made the impossible possible, said Glastian. He explained the importance of the event with numbers. Today, less than 2% of patients with diabetes receive modern treatment, although at least 20% need it. The main obstacle is the price: the treatment lasts for years, and many cannot afford it. Friday, which in terms of dosage is half price analogy, opened, he said, "a window of opportunity" for millions of people. For two months, almost 250,000 patients have already chosen the drug.